Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System

FDA approval of PerQseal Elite gives Haemonetics a new U.S. vascular closure product.

What the company is saying

Haemonetics Corporation is announcing U.S. FDA approval for the PerQseal Elite vascular closure system, positioning it as an innovative, sutureless solution for large-bore arterial procedures. The company frames this as a strategic expansion of its U.S. portfolio, following its January 2026 acquisition of Vivasure Medical Limited. The announcement highlights clinical evidence from the ELITE study, emphasizing 0% major complications per VARC-3 and a mean hemostasis time of less than one minute. Jan Hartmann, M.D., Senior Vice President and Chief Medical Officer, underscores the milestone’s importance for growth in advanced vascular closure and claims potential benefits for minimally invasive procedures like TAVR. The company also references prior CE Mark approval in Europe and plans to present further clinical data at the TCT Conference at the end of October. The tone is confident and focused on clinical validation and regulatory progress, with forward-looking statements about procedural simplification and patient experience.

What the data suggests

The FDA approval is a realised regulatory milestone, enabling commercial launch of PerQseal Elite in the U.S. for large-bore arterial procedures. The ELITE study reported 0% major complications per VARC-3 and a mean time to hemostasis of less than one minute, indicating strong clinical performance in a prospective, single-arm, multicenter setting. The device is compatible with 14–22F sheaths and can seal arteriotomies up to 26F, addressing a broad procedural range. CE Mark approval was granted in Europe in 2025 for both arterial and venous indications, suggesting prior regulatory and clinical validation outside the U.S. The company’s acquisition of Vivasure Medical Limited in January 2026 provided access to this technology. No financial metrics, adoption rates, or revenue projections are disclosed, so the commercial impact remains unquantified. The evidence supports the clinical and regulatory claims, but the absence of financial data leaves the economic upside undefined.

Analysis

The announcement is primarily factual, reporting FDA approval of the PerQseal Elite system, supported by specific clinical study results (0% major complications, <1 minute hemostasis) and prior CE Mark approval. The tone is positive but proportionate to the regulatory and clinical milestones achieved. Forward-looking statements are limited to potential procedural simplification and patient comfort, which are clearly identified as potential rather than guaranteed outcomes. There is a large capital outlay (Vivasure Medical acquisition), but the regulatory milestone is already realised, and the product is now approved for use in the U.S. However, no financial metrics (revenue, profit, cash flow) are disclosed, so the investment impact cannot be fully assessed. The gap between narrative and evidence is minimal; the only inflation is in aspirational language about future procedural benefits, which is clearly separated from the realised regulatory and clinical facts.

Risk flags

• ●Commercial adoption risk is significant, as no data on initial orders, hospital uptake, or physician adoption rates are disclosed. Without early sales figures, the pace and scale of market penetration are uncertain.
• ●Financial impact is undefined; the announcement provides no information on expected revenue, pricing, or margins for PerQseal Elite. This limits the ability to assess return on the Vivasure Medical acquisition or the contribution to Haemonetics’ overall financial performance.
• ●Competitive risk exists in the large-bore vascular closure market, where established alternatives may challenge PerQseal Elite’s adoption despite its clinical profile. The announcement does not address competitive positioning or differentiation beyond clinical study results.

Bottom line

Haemonetics’ FDA approval for PerQseal Elite is a concrete regulatory and clinical milestone, enabling immediate U.S. commercial launch of a sutureless, bioabsorbable vascular closure device. Clinical data from the ELITE study—0% major complications and rapid hemostasis—support the product’s safety and efficacy claims. The acquisition of Vivasure Medical Limited in January 2026 brought this technology into Haemonetics’ portfolio, and prior CE Mark approval in Europe indicates broader regulatory acceptance. However, the announcement omits any financial guidance, adoption metrics, or commercial rollout details, so the revenue and profit impact is unknown. Investors should focus on forthcoming updates about sales traction, hospital adoption, and competitive response. The most important takeaway is that Haemonetics has achieved a key regulatory milestone, but the economic value will only become clear as commercial data emerges.

Announcement summary

(NYSE:HAE) Haemonetics Corporation announced that the U.S. Food and Drug Administration (FDA) has approved the PerQseal® Elite vascular closure system for large-bore arterial procedures. This approval expands Haemonetics' portfolio of large-bore closure devices for structural heart and endovascular procedures in the U.S., following its acquisition of Vivasure Medical Limited in January 2026. The PerQseal Elite system is designed to provide sutureless, large-bore vascular closure for procedures performed with 14 – 22F sheaths. The system uses a fully bioabsorbable patch to seal arteriotomies up to 26F from within the vessel, enabling near-instantaneous hemostasis and leaving nothing permanent behind. Physicians can confirm hemostasis while maintaining guidewire access and have the flexibility to reposition or recover the system until implant release. Results from the prospective, single-arm, multicenter ELITE arterial study showed 0% major complications per VARC-3 and a mean time to hemostasis of less than one minute. In 2025, PerQseal Elite received CE Mark approval in Europe for both arterial and venous indications. Jan Hartmann, M.D., Senior Vice President and Chief Medical Officer at Haemonetics, stated that FDA approval is an important milestone in the company's strategy to grow its advanced vascular closure business and that PerQseal Elite could simplify minimally invasive procedures such as TAVR while supporting patient comfort. Professor Nicolas van Mieghem, MD, co-investigator of the ELITE study and interventional cardiologist at ZOL Hospital in Genk, Belgium, commented that PerQseal Elite is easy to adopt, intuitive to use, and integrates well into procedural workflows for large-bore arterial interventions. Haemonetics will present and discuss clinical data related to PerQseal Elite at the Transcatheter Cardiovascular Therapeutics® (TCT) Conference at the end of October.

Disagree with this article?